Effects of pyridostingmine on acetylcholinesterase in different muscles of the mouse

1 Pyridostigmine bromide was administered subcuta neously in mice, in a dose of 0.4 or 2.0 ?moles/kg, and the activity of the predominant (G1, G4, and A12) molecular forms of acetylcholinesterase were exam ined in diaphragm, extensor digitorum longus (EDL), and soleus muscles at 3 h, 6 h, 24 h and 5 days. 2 In diaphragm, no effect was apparent after the low dose, but after the high dose there was a reduction in activity of the functional A12 form at 24 h, followed by an increase which had overshot the control level at 5 days. 3 In the fast EDL, after the low dose, all three molecular forms were decreased at 3 h, but had returned to normal by 6 h. This effect was not apparent after the high dose. 4 In the slow soleus the low dose caused a significant increase in total enzyme activity at 5 days, but the high dose caused significant increases in all molecular forms at 3 hours. 5 Thus pyridostigmine had delayed effects on the levels of acetylcholinesterase. The three muscles displayed different sensitivities to the drug, but the changes were consistent with initial inhibition of the activity leading to down-regulation of the enzyme followed by up- regulation, which could overshoot the normal levels.

[1]  A. Spurgeon,et al.  Neuropsychological effects of long-term exposure to organophosphates in sheep dip , 1995, The Lancet.

[2]  S. Brimijoin,et al.  Slow accumulation of acetylcholinesterase in rat brain during enzyme inhibition by repeated dosing with chlorpyrifos. , 1995, Biochemical pharmacology.

[3]  R. Komel,et al.  Myoblast fusion and innervation with rat motor nerve alter distribution of acetylcholinesterase and its mRNA in cultures of human muscle , 1995, Neuron.

[4]  J. Wetherell Continuous Administration of Low Dose Rates of Physostigmine and Hyoscine to Guinea‐pigs Prevents the Toxicity and Reduces the Incapacitation Produced by Soman Poisoning , 1994, The Journal of pharmacy and pharmacology.

[5]  A. Maelicke,et al.  Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. , 1993, The Journal of pharmacology and experimental therapeutics.

[6]  P. Taylor,et al.  Control of acetylcholinesterase gene expression during myogenesis , 1993, Neuron.

[7]  A. Smith,et al.  Long‐term Effects of the Anticholinesterases Sarin and Soman on Latencies of Muscle Action Potentials in Mouse Diaphragm Muscle , 1993, The Journal of pharmacy and pharmacology.

[8]  B. P. Doctor,et al.  Comparison of antidote protection against soman by pyridostigmine, HI-6 and acetylcholinesterase. , 1993, The Journal of pharmacology and experimental therapeutics.

[9]  P. Taylor,et al.  Gene structure of mammalian acetylcholinesterase. Alternative exons dictate tissue-specific expression. , 1991, The Journal of biological chemistry.

[10]  A. Relman Tacrine as a Treatment for Alzheimer's Dementia , 1991 .

[11]  S. Bavari,et al.  Inhibition of human serum complement activity by diisopropylfluorophosphate and selected anticholinesterase insecticides. , 1989, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[12]  A. Kling,et al.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.

[13]  S. Younkin,et al.  Assembly of monomeric acetylcholinesterase into tetrameric and asymmetric forms. , 1986, The Journal of biological chemistry.

[14]  U. Maier,et al.  Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis , 1985, Clinical pharmacology and therapeutics.

[15]  D. Smyth,et al.  Evidence for the Neurotrophic Regulation of Collagen‐Tailed Acetylcholinesterase in Immature Skeletal Muscle by β‐Endorphin , 1984, Journal of neurochemistry.

[16]  S. Wall,et al.  L-glutamic acid, a neurotrophic factor for maintenance of acetylcholinesterase and butyrylcholinesterase in the preganglionically denervated superior cervical ganglion of the cat. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Haynes,et al.  Selective inhibition of ‘motor endplate-specific’ acetylcholinesterase by β-endorphin and related peptides , 1982, Neuroscience.

[18]  P. DIRNHUBER,et al.  The protection of primates against soman poisoning by pretreatment with pyridostigmine , 1979, The Journal of pharmacy and pharmacology.

[19]  M. Schwartz,et al.  Neostigmine‐induced end‐plate proliferation in the rat , 1977, Neurology.

[20]  R. L. Russell,et al.  A rapid, simple radiometric assay for cholinesterase, suitable for multiple determinations. , 1975, Analytical biochemistry.

[21]  B. Goodwin,et al.  EFFECTS OF SPINAL CORD AND SUBSTRATE ON ACETYLCHOLINESTERASE IN CHICK EMBRYONIC SKELETAL MUSCLE. , 1965, Developmental biology.

[22]  B. Vallee,et al.  ZINC, A COMPONENT OF YEAST ALCOHOL DEHYDROGENASE. , 1955, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Lardy,et al.  Purification and Kinetics of beta - delta-Galactosidase from Escherichia coli, Strain K-12 - Correction , 1953 .

[24]  H. Lardy,et al.  Purification and Kinetics of β-D-Galactosidase from Escherichia coli, Strain K-121,2 , 1953 .

[25]  A. Maelicke,et al.  A novel agonist binding site on nicotinic acetylcholine receptors. , 1993, Journal of receptor research.

[26]  P. Taylor,et al.  The cholinesterases. , 1991, The Journal of biological chemistry.

[27]  J. Massoulie,et al.  The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. , 1982, Annual review of neuroscience.